Tenofovir DF in antiretroviral-experienced patients: Results from a 48-week, randomized, double-blind study

AIDS

Volumn 16, Issue 9, 2002, Pages 1257-1263

  Schooley, Robert T ^a   Ruane, Peter ^a   Myers, Robert A ^a   Beall, Gildon ^a   Lampiris, Harry ^a   Berger, Daniel ^a   Chen, Shan Shan ^a   Miller, Michael D ^a   Isaacson, Erica ^a   Cheng, Andrew K ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

AIDS; Antiretroviral experienced; HIV; PMPA; TDF; Tenofovir DF

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; NUCLEOSIDE; PLACEBO; TENOFOVIR DISOPROXIL; VIRUS RNA; ADENINE; DRUG DERIVATIVE; ORGANOPHOSPHORUS COMPOUND; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; VIRUS MUTATION; VIRUS RESISTANCE; ANTIBIOTIC RESISTANCE; CD4 LYMPHOCYTE COUNT; DRUG EFFECT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; PHASE 2 CLINICAL TRIAL; PHYSIOLOGY; TIME; VIROLOGY;

ADENINE; ADULT; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMAN; MALE; ORGANOPHOSPHORUS COMPOUNDS; RNA, VIRAL; TIME FACTORS; HUMANS; PHOSPHONIC ACIDS;

EID: 0037076711     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200206140-00008     Document Type: Article

References (10)

1. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: Potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine
2. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl) PMPA
3. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA
4. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides
5. Patterns of HIV drug resistance in routine clinical practice: A survey of almost 12,000 samples from the USA in 1999
6. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults
7. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan
8. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF
9. The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: Results from a randomized, double-blind trial, CNA3002 European Study Team